TY - JOUR
T1 - Invasive lobular carcinoma of the breast
T2 - metastatic patterns and treatment modalities—a review
AU - Yu, Bixin
AU - Yan, Li
AU - Wang, Hong Yan
AU - Yang, Jin
AU - Yang, Jiao
N1 - Publisher Copyright:
Copyright © 2025 Yu, Yan, Wang, Yang and Yang.
PY - 2025
Y1 - 2025
N2 - Compared with invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC) exhibits distinct histologic, molecular, and clinical characteristics, including unique metastatic patterns. This review focuses on three major aspects: (1) an analysis of metastatic behavior across different ILC histologic subtypes, with a preliminary exploration of potential correlations with molecular features; (2) a synthesis of current treatment strategies, highlighting challenges such as endocrine resistance, limited tailored protocols, and emerging immunotherapeutic opportunities; and (3) a review of clinical trials from 2022 to 2024 to identify evolving strategies and future directions for individualized therapy. By integrating pathology, molecular profiling, and clinical data, this review emphasizes ILC’s distinctive metastatic behavior and unmet clinical needs, providing a conceptual framework to guide future translational research and therapeutic development.
AB - Compared with invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC) exhibits distinct histologic, molecular, and clinical characteristics, including unique metastatic patterns. This review focuses on three major aspects: (1) an analysis of metastatic behavior across different ILC histologic subtypes, with a preliminary exploration of potential correlations with molecular features; (2) a synthesis of current treatment strategies, highlighting challenges such as endocrine resistance, limited tailored protocols, and emerging immunotherapeutic opportunities; and (3) a review of clinical trials from 2022 to 2024 to identify evolving strategies and future directions for individualized therapy. By integrating pathology, molecular profiling, and clinical data, this review emphasizes ILC’s distinctive metastatic behavior and unmet clinical needs, providing a conceptual framework to guide future translational research and therapeutic development.
KW - endocrine resistance
KW - invasive lobular carcinoma
KW - metastatic pattern
KW - prognosis
KW - treatment mode
UR - https://www.scopus.com/pages/publications/105018810337
U2 - 10.3389/fonc.2025.1631670
DO - 10.3389/fonc.2025.1631670
M3 - 文献综述
AN - SCOPUS:105018810337
SN - 2234-943X
VL - 15
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 1631670
ER -